1 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Joint Bone Spine
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le mercredi 11 mars 2020
Doi : 10.1016/j.jbspin.2020.02.004
accepted : 12 February 2020
Patients with axial spondyloarthritis report significant differences between men and women and high impact of the disease: Large websurvey analysis

Sebastian E. Ibáñez Vodnizza a, , 1 , Rianne E. van Bentum b, 1, Omar Valenzuela a, Irene E. van der Horst-Bruinsma b
a Department of Rheumatology, Clínica Alemana, Universidad del Desarrollo medicine Faculty, 1410, Av. Manquehue Norte, 7650567 Vitacura, Santiago, Chile 
b Department of Rheumatology, Amsterdam University Medical Center, location VUmc, 1117, De Boelelaan, 1081HV Amsterdam, Netherlands 

Corresponding author.

Women with axSpA in Chile report a higher levels of disease activity, daily life impairment and work disability, compared to men.
Women use less biologics despite a higher disease burden, which could suggest treatment inequality.
This study reveals the need to improve treatment access and gender inequality in Chilean axSpA.

The full text of this article is available in PDF format.

In axial spondyloarthritis (axSpA), mounting evidence shows female patients to experience a higher disease burden. These differences appear to be particularly large in South America. One explanation could be inequity in treatment access between men and women. The objective was to evaluate gender differences in disease burden and work participation, and the potential influence of treatment, in Latin American patients.


A cross sectional online survey among axSpA patients, collecting disease characteristics, treatment, disease burden (BASDAI, BASFI, ASAS Health Index) and work participation (WPAI). Associations between gender and disease burden or work participation were assessed through regression analyses, correcting for treatment.


AxSpA was reported by 472 participants (63% women) and disease activity (BASDAI4: 83%), ASASHI (≥moderately impaired: 91%) and work disability (absenteeism: 41%; presenteeism 82%) were high. Biological use was very low (20%), while 34% used opiates. Females had significantly higher BASDAI, ASAS HI, work absenteeism and presenteeism, although were less likely to receive biologics (26% versus 16%, P <0.01). Gender differences disappeared after correction for treatment.


This web survey in Latin American axSpA patients shows a high disease burden and work impairment. The use of biologics is low, while the use of opiates was alarmingly high. Women used significantly less biologics despite reporting a worse disease state and work disability, which could be due to treatment inequity.

The full text of this article is available in PDF format.

Keywords : Spondyloarthritis, Biologics, Gender, Burden, Chile

1  Both authors contributed equally to this work.

© 2020  Société française de rhumatologie@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline